Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT05549661

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Led by Mayo Clinic · Updated on 2026-02-23

25

Participants Needed

1

Research Sites

243 weeks

Total Duration

On this page

Sponsors

M

Mayo Clinic

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia and Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap neoplasms that has come back (recurrent) or that does not respond to treatment (refractory). Onvansertib is a drug that binds to and inhibits an enzyme called PLK1, preventing cancer cell proliferation and causing cell death.

CONDITIONS

Official Title

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • History of WHO-defined proliferative CMML or MDS/MPN overlap neoplasm with white blood cell count ≥ 13,000/mm³ at diagnosis
  • Relapsed or refractory after hydroxyurea treatment or at least 4 cycles of hypomethylating agents, or intolerant to these therapies
  • Able and willing to provide written informed consent
  • Willing to return for follow-up during the active monitoring phase
  • Willing to provide mandatory bone marrow and blood specimens for research
  • ECOG performance status 0, 1, or 2
  • Recovered to grade 1 or baseline from previous therapy side effects except alopecia
  • Platelet count ≥ 20,000/mm³ (or able to achieve with transfusion support)
  • Total bilirubin ≤ 1.5 x upper limit normal (ULN) or ≤ 3 x ULN if Gilbert's syndrome
  • ALT and AST ≤ 3 x ULN
  • Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min/m²
  • Ability to complete questionnaires alone or with help
  • For women of child-bearing potential: agreement to use contraception or abstain during the study and 180 days after
  • Negative serum or urine pregnancy test ≤ 7 days prior to registration
Not Eligible

You will not qualify if you...

  • Previous exposure to investigational PLK1 inhibitors
  • Transformation to acute leukemia on any prior bone marrow biopsy
  • Prior allogeneic stem cell transplant with active moderate to severe graft-versus-host disease
  • Active central nervous system disease
  • Concurrent active cancers except treated nonmelanoma skin cancer or certain other cured cancers without disease for over 2 years
  • NYHA class III/IV heart failure or active angina
  • Chemotherapy or biologic therapy (except hydroxyurea) within 2 weeks before pre-registration
  • Use of other investigational agents for primary disease
  • Major surgery within 6 weeks before pre-registration
  • Gastrointestinal disorders impairing oral drug absorption
  • Unable or unwilling to swallow study drug
  • Uncontrolled illness including infections, wounds, arrhythmias, pulmonary disease, or psychiatric/social issues
  • Active HIV, hepatitis B or C with measurable viral load; exceptions apply
  • Use of live vaccines ≤ 28 days before pre-registration
  • Systemic immunosuppression with steroids ≥ 20 mg/day prednisone equivalent
  • Any condition making study treatment unsafe or compliance unlikely
  • Use of strong CYP3A4 inhibitors or inducers
  • QTc interval > 470 ms (Fridericia's correction) unless corrected
  • Pregnancy, nursing, or unwillingness to use contraception if of childbearing potential
  • Increased risk of dangerous heart arrhythmias (Torsade des Pointes)
  • Transformation to acute leukemia at registration biopsy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Referral Office

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here